Skip to content
DraconiticResearch
Search Sources API
197,787 studies31 sourcesUpdated 49 min ago
Peer-reviewedCC BYJournal of intensive medicine

Sepsis-associated sarcopenia: Emerging insights into mechanisms and therapeutic approaches

  • Xiujun Chang1
  • Fan Zeng1
  • Jun Wang1
  • Zhaoxuan Guo1
  • Rongan Liu1
  • Yu Lei1
  • Jiajia Li1
  • Fuxun Yang1
  • Xiaoxiu Luo1
  • Chun Pan1
  • Xiaobo Huang1
  • Yunping Lan1
  1. 1Department of Intensive Care Unit, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, Sichuan, China
Read full textPDFDOICite

Abstract

As medical treatment advances, a growing proportion of sepsis patients survive from their initial critical illness. However, excessive treatment and diminished quality of life after discharge raise substantial concerns. Sarcopenia affects 40%–70% of sepsis survivors, manifesting as flaccid weakness in the extremities and diaphragm. This condition typically resolves within weeks or months, but in some cases, recovery does not occur and may last for 2 years after intensive care unit discharge. Consequently, sepsis patients with sarcopenia face an unfavorable long-term influence, and they also consume considerable medical resources. The mechanisms and treatments of sepsis-associated sarcopenia (SASP) are increasingly recognized as research priorities. This review provides a comprehensive analysis of molecular mechanisms, measuring parameters, and therapeutic approaches for SASP.

Related

  1. Therapeutic Strategies After Immunotherapy Failure in Advanced Non-Small Cell Lung Cancer: Mechanisms of Resistance and Emerging Treatment Approaches
    Masatoshi Kanayama, Masaru Takenaka, Hidetaka Uramoto
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  2. The gasdermin family in depression-associated neuroinflammation: established evidence, emerging mechanisms, and therapeutic perspectives
    Yang Luo, Ziming Liu, Huiqin Li +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  3. MTAP Loss and Pleural Mesothelioma (PM): Current Treatment Strategies and Emerging Therapeutic Approaches
    Susana Cedres, Laura Masfarre, Ilaria Priano +14
    CancersPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  4. Molecularly guided pharmacotherapy for obesity: emerging targets, clinical efficacy, and personalized therapeutic approaches
    Jianchao Mao, Rong Hu
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossref
  5. Corneal Nerve Injury and Regeneration: Mechanisms, Clinical Consequences, and Emerging Therapeutic Strategies.
    Athar Shadmani, Anat Galor, Houri Esmaeilkhanian +1
    DrugsPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{chang2026sepsisassociated,
  title = {{Sepsis-associated sarcopenia: Emerging insights into mechanisms and therapeutic approaches}},
  author = {Xiujun Chang and Fan Zeng and Jun Wang and Zhaoxuan Guo and Rongan Liu and Yu Lei and Jiajia Li and Fuxun Yang and Xiaoxiu Luo and Chun Pan and Xiaobo Huang and Yunping Lan},
  journal = {Journal of intensive medicine},
  year = {2026},
  month = may,
  doi = {10.1016/j.jointm.2026.03.005},
  url = {https://europepmc.org/article/PMC/PMC13728391},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Sepsis-associated sarcopenia: Emerging insights into mechanisms and therapeutic approaches
AU  - Xiujun Chang
AU  - Fan Zeng
AU  - Jun Wang
AU  - Zhaoxuan Guo
AU  - Rongan Liu
AU  - Yu Lei
AU  - Jiajia Li
AU  - Fuxun Yang
AU  - Xiaoxiu Luo
AU  - Chun Pan
AU  - Xiaobo Huang
AU  - Yunping Lan
PY  - 2026
DA  - 2026/05/18
JO  - Journal of intensive medicine
DO  - 10.1016/j.jointm.2026.03.005
UR  - https://europepmc.org/article/PMC/PMC13728391
AB  - As medical treatment advances, a growing proportion of sepsis patients survive from their initial critical illness. However, excessive treatment and diminished quality of life after discharge raise substantial concerns. Sarcopenia affects 40%–70% of sepsis survivors, manifesting as flaccid weakness in the extremities and diaphragm. This condition typically resolves within weeks or months, but in some cases, recovery does not occur and may last for 2 years after intensive care unit discharge. Consequently, sepsis patients with sarcopenia face an unfavorable long-term influence, and they also consume considerable medical resources. The mechanisms and treatments of sepsis-associated sarcopenia (SASP) are increasingly recognized as research priorities. This review provides a comprehensive analysis of molecular mechanisms, measuring parameters, and therapeutic approaches for SASP.
SN  - 2097-0250
SN  - 2667-100X
ER  -